Day One Biopharmaceuticals, Inc. (DAWN)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation

Ask a question about Day One Biopharmaceuticals, Inc. (DAWN)

Company Performance

Current Price

as of Oct 23, 2024

$14.33

P/E Ratio

N/A

Market Cap

$1.26B

Description

Day One Biopharmaceuticals, Inc. operates as a holding company. The firm through its subsidiary develops and commercializes targeted therapies for patients of all ages with genetically defined cancers. Its products include DAY101 and pimsertib. The company was founded by Julie Grant and Samuel Blackman in November 2018 and is headquartered in Brisbane, CA.

Metrics

Overview

HQBrisbane, CA
SectorHealth Technology
IndustryPharmaceuticals: Major
TickerDAWN
Price$14.33-0.90%

Trading Information

Market Cap$1.26B
Float67.59%
Average Daily Volume (1m)1,003,499
Average Daily Volume (3m)1,002,283
EPS-$1.93

Company

Revenue$8.19M
Rev Growth (1yr)N/A
Net Income-$4.41M
Gross Margin91.37%
EBITDA Margin-1,396.47%
EBITDA-$114.40M

EV$838.86M
EV/Revenue102.40
P/EN/A
P/S152.40
P/B4.10

Documents

Factset Street Account

Day One Biopharmaceuticals reports Q3 EPS ($0.54) vs FactSet ($0.59) [10 est, ($0.70)-(0.44)] ($12.19, 0.00) (2023-11-06T21:35:29Z)

Day One announces tovorafenib FIREFLY-1 data published in Nature Medicine ($11.72, 0.00) (2023-11-17T12:04:31Z)

Day One announces FDA Acceptance of NDA and Priority Review for Tovorafenib in relapsed or progressive Pediatric Low-Grade Glioma (pLGG) ($10.17, 0.00) (2023-10-30T12:01:29Z)

Factset

Factset Business Description